Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06566391 | Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma | unknown | Phase 2 | 35 | European Institute of OncologyOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT06556004 | Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients(Trimelvax001) | unknown | Phase 1 | 20 | University of ChileOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04951583 | Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma(FMT-LUMINATE) | unknown | Phase 2 | 45 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT04272658 | PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy(IMMUNOPET2) | unknown | — | 56 | University Hospital, BrestOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06414343 | LATe TreatmENT Related Toxicity in Melanoma (LATENT)(LATENT) | unknown | — | 400 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors(TIG-006) | unknown | Phase 1 / Phase 2 | 153 | iTeos Belgium SAINDUSTRY | 6 | Jun 21, 2024 | clinicaltrials |
| NCT06254196 | Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies(Telenursing) | unknown | N/A | 40 | Regina Elena Cancer InstituteOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05075356 | iToBoS: Clinical Data Acquisition Study(iToBoS) | unknown | N/A | 600 | The University of QueenslandOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT04193956 | POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors(POINTING) | unknown | — | 3,500 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06116461 | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response(NIVOPTIMIZE) | unknown | Phase 4 | 34 | Erasmus Medical CenterOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT05520294 | Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma | unknown | — | 90 | University of Colorado, DenverOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06321640 | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.(POSITive) | unknown | — | 265 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06299878 | MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns](CRISTINA) | unknown | — | 72 | Russian Academy of Medical SciencesOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06280040 | Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma | unknown | — | 20 | Medical University of ViennaOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04879654 | Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery(SNMM) | unknown | Phase 2 | 45 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06294379 | Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy | unknown | — | 150 | Odense University HospitalOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06284512 | Uveal Melanoma - Comparative Study | unknown | — | 50 | Medical University of ViennaOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06281912 | Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients(MELCAYA) | unknown | — | 70 | Azienda Ospedaliera di PerugiaOTHER | 7 | Feb 28, 2024 | clinicaltrials |
| NCT05135715 | A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) | unknown | Phase 2 | 50 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06254547 | Leaderboard Influence on Self-Regulated Training in a Gamified Dermoscopy Training App | unknown | N/A | 150 | Herlev HospitalOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT06246903 | INTER-PATHOLOGIST READER STUDY | unknown | — | 500 | Orlucent, IncINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06239623 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | unknown | Phase 1 | 60 | JS InnoPharm, LLCINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06236360 | Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet(MINI-MD) | unknown | N/A | 30 | University Hospital RijekaOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03068624 | Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | unknown | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT00368615 | Characterization of the Melanoma-Specific Immune Response(Melanoma) | unknown | — | 20 | University of California, DavisOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06207747 | Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma Patients | unknown | N/A | 70 | Institute of Oncology LjubljanaOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04720768 | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE(CELEBRATE) | unknown | Phase 1 / Phase 2 | 78 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT02557321 | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 50 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02977052 | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab(OpACIN-neo) | unknown | Phase 2 | 186 | The Netherlands Cancer InstituteOTHER | 4 | Nov 15, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05370807 | A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma(RegoMel) | unknown | Phase 2 | 48 | Universitair Ziekenhuis BrusselOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05466474 | PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06080711 | AI-Augmented Skin Cancer Diagnosis in Teledermatoscopy(AIDMel) | unknown | N/A | 30 | Karolinska University HospitalOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06073548 | Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study(SALOME Quali) | unknown | — | 250 | Institut CurieOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT04546074 | Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma | unknown | Phase 1 / Phase 2 | 22 | Keio UniversityOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT01586767 | Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy | unknown | N/A | 45 | Massachusetts General HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04986696 | Irradiation of Melanoma in a Pulse(IMPulse) | unknown | N/A | 46 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05986331 | Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma | unknown | Phase 3 | 366 | BiocadINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06041724 | Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma | unknown | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT04799106 | Community Based Strategies for Early Detection of Melanoma | unknown | — | 200 | Cedars-Sinai Medical CenterOTHER | 0 | Aug 29, 2023 | clinicaltrials |
| NCT03808441 | CAcTUS - Circulating Tumour DNA Guided Switch(CAcTUS) | unknown | Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05990634 | LifeChamps Feasibility Study | unknown | N/A | 20 | Region StockholmOTHER_GOV | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05984108 | Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System(MelaMen) | unknown | — | 50 | Central Hospital, Nancy, FranceOTHER | 1 | Aug 9, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Oct 2, 2024source: clinicaltrials